Transmissibility, infectivity and immunogenicity of a live human parainfluenza type 3 virus vaccine (HPIV3cp45) among susceptible infants and toddlers

Shabir A. Madhi, Clare Cutland, Yuwei Zhu, Jill G. Hackell, Frances Newman, Nigel Blackburn, Brian R. Murphy, Robert B. Belshe, Ruth A Karron, Anne M. Deatly, William C. Gruber, David I. Bernstein, Peter F. Wright

Research output: Contribution to journalArticle


Background: This study examined the transmissibility between young children of an intranasally administered live attenuated human parainfluenza virus type 3 (HPIV3)-cp45 vaccine candidate. Methods: Eighty subjects were enrolled in playgroups among whom there was at least one infected vaccinee in close contact with a seronegative placebo recipient over 21 days without a confounding infection with wtHPIV3. Following vaccination viral cultures were obtained on nine occasions to detect shedding and transmission of HPIV3cp45. Serum antibody titers were measured before and 7 weeks after vaccination. Results: No child fulfilled the criteria for transmission of HPIV3cp45 giving a risk of transmission of 0.04 (95% CI 0.01-0.19), hence establishing that HPIV3cp45 is less infectious than wtHPIV3 and risk of transmission is not a limitation to further clinical development of this vaccine candidate.

Original languageEnglish (US)
Pages (from-to)2432-2439
Number of pages8
Issue number13
Publication statusPublished - Mar 20 2006



  • Immunogenicity
  • Live-attenuated
  • Parainfluenza virus type 3
  • Safety
  • Transmissibility
  • Vaccine

ASJC Scopus subject areas

  • Immunology
  • Microbiology
  • Virology
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)

Cite this